Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, will present results from the Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral presentation at a late breaker session of the XVII International AIDS Conference in Mexico City on August 7, 2008. RDEA806 is the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV).

Presentation Details

Date/Time: Thursday, August 7, 2008 from 2:30 p.m. - 4:00 p.m. CDT

Abstract Title: "Antiviral activity of RDEA806, a novel HIV non-nucleoside

reverse transcriptase inhibitor, in treatment of naive HIV patients"

Session Title: THAB04 - Late Breaker Track B, Session 2

Location: Centro Banamex -- Session Room 1 (Abstract #THAB0403)

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
2. Craig Johnson Joins Ardea Biosciences Board of Directors
3. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
4. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
5. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
6. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
7. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
8. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):